Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

New England Journal of Medicine

Volumn 345, Issue 12, 2001, Pages 851-860

  Lewis, Edmund J ^a   Hunsicker, Lawrence G ^b   Clarke, William R ^c   Berl, Tomas ^d   Pohl, Marc A ^e   Lewis, Julia B ^f   Ritz, Eberhard ^g   Atkins, Robert C ^h   Rohde, Richard ^a   Raz, Itamar ⁱ  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h Monash Medical Center   (Australia)

ⁱ HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CALCIUM CHANNEL BLOCKERS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0035922447     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa011303     Document Type: Article

References (26)

1. Diabetes trends in the U.S.: 1990-1998
2. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
3. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade
4. Effect of diuretic-based antihypertensive treatment of cardiovascular disease risk in older diabetic patients with isolated systolic hypertension
5. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension
6. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
7. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
8. The Irbesartan Type II Diabetic Nephropathy Trial: Study design and baseline patient characteristics
9. Discrete sequential boundaries for clinical trials
10. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition
11. Renal hemodymanic response to an angiotensin II antagonist, eprosartan, in healthy men
12. The paradox of the low-renin state in diabetic nephropathy
13. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans
14. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
15. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation
16. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells
17. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells
18. Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury
19. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
20. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
21. Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: Results of prospectively designed overviews of randomized trials
22. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study